Relative importance of apoptosis and cell cycle blockage in the synergistic effect of combined R115777 and imatinib treatment in BCR/ABL-positive cell lines

Biochemical Pharmacology

Volumn 69, Issue 11, 2005, Pages 1585-1594

  Miyoshi, Takuji ^a   Nagai, Tadashi ^a   Ohmine, Ken ^a   Nakamura, Makiko ^a   Kano, Yasuhiko ^b   Muroi, Kazuo ^a   Komatsu, Norio ^a   Ozawa, Keiya ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOCHIGI CANCER CENTER   (Japan)

Author keywords

BCR ABL; Chronic myeloid leukemia; Drug resistance; Farnesyltransferase inhibitor; Imatinib; R115777

Indexed keywords

BCR ABL PROTEIN; CASPASE 3; CYCLIN DEPENDENT KINASE INHIBITOR 1B; IMATINIB; LIPOCORTIN 5; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TIPIFARNIB;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; DRUG POTENTIATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLAST CRISIS; CELL CYCLE; CELL LINE, TUMOR; DRUG RESISTANCE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; GROWTH INHIBITORS; HUMANS; LEUKEMIA; PIPERAZINES; PYRIMIDINES; QUINOLONES;

EID: 19344369441     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.02.021     Document Type: Article

References (49)

1. H. Kantarjian, C. Sawyers, A. Hochhaus, F. Guilhot, C. Schiffer, and C. Gambacorti-Passerini Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia N Engl J Med 346 2002 645 652
2. T.P. Hughes, J. Kaeda, S. Branford, Z. Rudzki, A. Hochhaus, and M.L. Hensley Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia N Engl J Med 349 2003 1423 1432
3. C.L. Sawyers, A. Hochhaus, E. Feldman, J.M. Goldman, C.B. Miller, and O.G. Ottmann Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood 99 2002 3530 3539
4. B.J. Druker, C.L. Sawyers, H. Kantarjian, D.J. Resta, S.F. Reese, and J.M. Ford Activity of a specific inhibitor of the BCR/ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med 344 2001 1038 1042
5. N.P. Shah, J.M. Nicoll, B. Nagar, M.E. Gorre, R.L. Paquette, and J. Kuriyan Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia Cancer Cell 2 2002 117 125
6. M.E. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, and P.N. Rao Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation of amplification Science 293 2001 876 880
7. S. Branford, Z. Rudzki, S. Walsh, A. Grigg, C. Arthur, and K. Taylor High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance Blood 99 2002 3472 3475
8. N. von Bubnoff, F. Schneller, C. Peschel, and J. Duyster BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukemia to STI571: a prospective study Lancet 359 2002 487 491
9. C. Ricci, B. Scappini, V. Divoky, S. Gatto, F. Onida, and S. Verstovsek Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line Cancer Res 62 2002 5995 5998
10. P. le Coutre, E. Tassi, M. Varella-Garcia, R. Barni, L. Mologni, and G. Cabrita Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification Blood 95 2000 1758 1766
11. E. Weisberg, and J.D. Griffin Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines Blood 95 2000 3498 3505
12. F.X. Mahon, M.W. Deininger, B. Schultheis, J. Chabrol, J. Reiffers, and J.M. Goldman Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance Blood 96 2000 1070 1079
13. + leukemic cells to the Abl inhibitor STI571 J Natl Cancer Inst 92 2000 1641 1650
14. T. Tarumoto, T. Nagai, K. Ohmine, T. Miyoshi, M. Nakamura, and T. Kondo Ascorbic acid restores the sensitivity to imatinib through suppression of Nrf2-dependent gene expression in a imatinib-resistant cell line, KCL22/SR Exp Hematol 32 2004 375 381
15. C. Roche-Lestienne, V. Soenen-Cornu, N. Grardel-Duflos, J.L. Lai, N. Philippe, and T. Facon Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment Blood 100 2002 1014 1018
16. K.A. Kreuzer, P. Le Coutre, O. Landt, I.K. Na, M. Schwarz, and K. Schultheis Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique Ann Hematol 82 2003 284 289
17. W.K. Hofmann, M. Komor, B. Wassmann, L.C. Jones, H. Gschaidmeier, and D. Hoelzer Presence of the BCR-ABL mutation Glu255Lys prior to STI571 (imatinib) treatment in patients with Ph+ acute lymphoblastic leukemia Blood 102 2003 659 661
18. P. La Rosee, A.S. Corbin, E.P. Stoffregen, M.W. Deininger, and B.J. Druker Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571) Cancer Res 62 2002 7149 7153
19. B.M. Mow, J. Chandra, P.A. Svingen, C.G. Hallgren, E. Weisberg, and T.J. Kottke Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro Blood 99 2002 664 671
20. B. Nagar, W.G. Bornmann, P. Pellicena, T. Schindler, D.R. Veach, and W.T. Miller Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571) Cancer Res 62 2002 4236 4243
21. D. Wisniewski, C.L. Lambek, C. Liu, A. Strife, D.R. Veach, and B. Nagar Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases Cancer Res 62 2002 4244 4255
22. A.J. Tipping, and J.V. Melo Imatinib mesylate in combination with other chemotherapeutic drugs: in vitro studies Semin Hematol 40 Suppl. 2 2003 83 91
23. B.J. Druker Overcoming resistance to imatinib by combining targeted agents Mol Cancer Ther 2 2003 225 226
24. E.K. Rowinsky, J.J. Windle, and D.D. Von Hoff Ras protein farnesyltransferase: a strategic target for anticancer therapeutic development J Clin Oncol 17 1999 3631 3652
25. R.A. Gibbs Farnesyltransferase inhibitors: novel anticancer mechanisms and new therapeutic applications Curr Opin Drug Dis Dev 3 2000 585 596
26. N.E. Kohl, C.A. Omer, M.W. Conner, N.J. Anthony, J.P. Davide, and S.J. deSolms Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice Nat Med 1 1995 792 797
27. H.R. Ashar, L. James, K. Gray, D. Carr, S. Black, and L. Armstrong Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules J Biol Chem 275 2000 30451 30457
28. P.F. Lebowitz, and G.C. Prendergast Non-Ras targets of farnesyltransferase inhibitors: focus on Rho Oncogene 17 1998 1439 1445
29. D.G. Peters, R.R. Hoover, M.J. Gerlach, E.Y. Koh, H. Zhang, and K. Choe Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia Blood 97 2001 1404 1412
30. A. Reichert, N. Heisterkamp, G.Q. Daley, and J. Groffen Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336 Blood 97 2001 1399 1403
31. R.R. Hoover, F.X. Mahon, J.V. Melo, and G.Q. Daley Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336 Blood 100 2002 1068 1071
32. J.E. Karp, J.E. Lancet, S.H. Kaufmann, D.W. End, J.J. Wright, and K. Bol Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial Blood 97 2001 3361 3369
33. J. Cortes, M. Albitar, D. Thomas, F. Giles, R. Kurzrock, and A. Thibault Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies Blood 101 2003 1692 1697
34. J. Cortes, G. Garcia-Manero, S. O'Brien, I. Hernandez, W. Rackoff, and S. Faderl Phase I study of a imatinib and Tipifarnib (Zarnestra™, R115777) in patients with chronic myeloid leukemia in chronic phase refractory to imatinib Blood 102 2003 909a
35. J. Gotlib, M. Mauro, M.E. O'Dwyer, L. Fechter, K. Dugan, and J. Kuyl Tipifarnib (Zarnestra™) and imatinib (Gleevec™) combination therapy in patients with advanced chronic myelogenous leukemia (CML): preliminary results of a phase I study Blood 102 2003 909a
36. K. Ohmine, T. Nagai, T. Tarumoto, T. Miyoshi, K. Muroi, and H. Mano Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR Stem Cells 21 2003 315 321
37. G.G. Steel, and M.J. Peckham Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity Int J Radiat Oncol Biol Phys 5 1979 85 91
38. Y. Kano, M. Akutsu, S. Tsunoda, H. Mano, Y. Sato, and Y. Honma In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents Blood 97 2001 1999 2007
39. A.B. Lassar, R.L. Davis, W.E. Wright, T. Kadesch, C. Murre, and A. Voronova Functional activity of myogenic HLH proteins requires hetero-oligomerization with E12/E47-like proteins in vivo Cell 66 1991 305 315
40. T. Nagai, H. Harigae, H. Ishihara, H. Motohashi, N. Minegishi, and S. Tsuchiya Transcription factor GATA-2 is expressed in erythroid, early myeloid, and CD34+ human leukemia-derived cell lines Blood 84 1994 1074 1084
41. A.A. Adjei, J.N. Davis, C. Erlichman, P.A. Svingen, and S.H. Kaufmann Comparison of potential markers of farnesyltransferase inhibition Clin Cancer Res 6 2000 2318 2325
42. A. Hochhaus Cytogenetic and molecular mechanisms of resistance to imatinib Semin Hematol 40 2003 69 79
43. F.X. Mahon, F. Belloc, V. Lagarde, C. Chollet, F. Moreau-Gaudry, and J. Reiffers MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models Blood 101 2003 2368 2373
44. P.T. Ferrao, M.J. Frost, S.P. Siah, and L.K. Ashman Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro Blood 102 2003 4499 4503
45. A. Jacquel, M. Herrant, L. Legros, N. Belhacene, F. Luciano, and G. Pages Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl-positive K562 cell line and its differentiation towards the erythroid lineage FASEB J 17 2003 2160 2162
46. N. Komatsu, T. Watanabe, M. Uchida, M. Mori, K. Kirito, and S. Kikuchi A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells J Biol Chem 278 2003 6411 6419
47. H.R. Ashar, L. James, K. Gray, D. Carr, S. Black, and L. Armstrong Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules J Biol Chem 275 2000 30451 30457
48. H.R. Ashar, L. James, K. Gray, D. Carr, M. McGuirk, and E. Maxwell The farnesyl transferase inhibitor SCH 66336 induces a G(2) → M or G(1) pause in sensitive human tumor cell lines Exp Cell Res 262 2001 17 27
49. S.M. Graham, H.G. Jorgensen, E. Allan, C. Pearson, M.J. Alcorn, and L. Richmond Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro Blood 99 2002 319 325